Lauren Collen
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Characterization of Defective STAT3 Activation in Patients with VEOIBD
Open Date: 2022-07-01
Close Date: 2025-06-30
Articles (14)
Year:
2026
Background Pediatric Inflammatory Bowel Disease (IBD) is a chronic condition characterized by persistent intestinal inflammation in children. It often presents with distinct clinical phenotypes and is more frequently linked to rare monogenic variants affecting epithelial barrier function or mucosal immunity. Although over 100 genes are associated with monogenic IBD, their roles in the intestinal epithelium remain poorly defined. This study aimed to improve our understanding of epithelial dysfunction in early-onset IBD through molecular and cellular analyses to uncover patient-specific phenotypes and potential therapeutic targets. Methods We generated intestinal epithelial organoids (IEOs) from 94 pediatric IBD patients, including those with monogenic variants (BTK, TTC7A, IL10RA, LRBA, STXBP2, TRNT1, SKIV2L), along with 46 non-IBD controls. RNA sequencing was performed on 38 patient and 20 control lines, under both baseline conditions and after immunological stimulation, yielding a valuable dataset for studying epithelial responses in IBD. Results IEOs effectively initiated inflammation upon bacterial lysate stimulation, regardless of disease status, origin, or genotype. Inflammatory stimulation triggered upregulation of IBD-linked genes SERPINA1 and LIFR in IBD organoids, suggesting their role in epithelial innate immunity. However, network analysis showed no consistent transcriptional signatures across all IBD cases. Instead, specific genotypes (TTC7A, STXBP2, LRBA) revealed responses, with STXBP2 and LRBA showing shared upregulation of IL-1 and SLC30-mediated zinc trafficking pathways. Conclusions These findings underscore the potential of IEOs as a valuable model for studying IBD and offer key insights that could guide the development of targeted therapies for both monogenic and non-monogenic forms of IBD.
Year:
2026
Background and aims Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking. We assessed the therapeutic response to help close this gap. Methods This retrospective study involved 30 sites worldwide. Demographic, clinical, and laboratory data were collected from patients with VEO-IBD who commenced adalimumab therapy before the age of 6 years. Results Seventy-eight patients (37 Crohn’s disease, 26 ulcerative colitis, and 15 with IBD-unclassified) were included. Median age of IBD onset was 2.6 (1.3–4.1) years, with 30 (38.5%) patients diagnosed at age <2 years. Median age at adalimumab initiation was 4.2 (2.8-5.1) years. Adalimumab was used as second-line biologic therapy in 45 (57.7%) patients after infliximab. The median time to last follow-up was 63 (22-124) weeks. Significant improvement in clinical scores, CRP, fecal calprotectin, and weight Z-score were observed by Week 52. Adalimumab durability rates were 61.9%, 48.1%, and 35.6% after 1, 2, and 3 years, respectively. Drug discontinuation rates were not dependent on IBD type, age, prior anti-TNF exposure, or concomitant immunomodulatory treatment. Four (5.1%) patients developed serious infections, including 1 patient with TTC7A deficiency who died following adenovirus sepsis. Conclusion Adalimumab therapy is a viable therapeutic option in patients with VEO-IBD with an acceptable safety profile.
Year:
2025
Objectives South Asian pediatric inflammatory bowel disease (SA pIBD) is a novel at‐risk demographic group for pediatric IBD. However, the disease characteristics and treatment strategies for SA pIBD in the United States remain poorly described. Methods In this retrospective cohort study of 147 patients, SA patients with pIBD ( n = 55) were matched (~1:2) to non‐South Asian (NSA, n = 92) patients with pIBD by age, sex, and disease subtype. Study outcomes included demographics, disease extent and severity, treatments utilized, and patient perspectives on pIBD and its treatment. Results Among 55 SA and matched 92 NSA pIBD patients, mean age of presentation was 12 years old, with male predominance (65%), and majority with a Crohn's diagnosis (65%). Very early‐onset IBD (VEOIBD) was reported in 5.5% of SA pIBD. SA pIBD patients more frequently presented with weight loss, left‐sided disease, upper gastrointestinal manifestations, and elevated erythrocyte sedimentation rate. SA pIBD patients were less likely to use biologic therapies as their initial treatment (9.1% vs. 30.4%, p < 0.005), with a lower cumulative rate of biologic use. Instead, SA pIBD were more likely to use mesalamine or other treatments as their initial therapy. Conclusions SA pIBD had unique phenotypic characteristics compared to NSA pIBD. SA pIBD patients were less likely to initiate biologic therapies as their initial treatment and had a longer time‐to‐initiation of biologic therapies.
Year:
2025
Pediatric Inflammatory Bowel Disease (IBD) is a chronic condition characterized by per-sistent intestinal inflammation in children and adolescents. Despite a rising global incidence, the underlying causes and optimal management strategies for pediatric IBD are still not fully understood. Compared to adult IBD, pediatric IBD frequently presents with distinct disease phenotypes, and is more commonly linked to rare monogenic variants that cause intestinal epithelial barrier dysfunction or affect the function of mucosal immune cells. While more than 100 genes have been associated with early-onset IBD, the roles of many of these genes in the intestinal epithelium and the mechanisms by which genetic variants contribute to disease remain poorly defined. Here we aimed to improve our understanding of intestinal epithelium dysfunction in early-onset IBD by conducting extensive molecular and cellular characterization to gain insights into patient-specific epithelial phenotypes and identify therapeutic targets. We generated intestinal epithelial organoids (IEOs) from 94 pediatric IBD patients, representing diverse clinical characteristics and including those with monogenic variants ( BTK n=4, TTC7A n=3, IL10RA n=1, LRBA n=1, STXBP2 n=1, TTC37 n=1, TRNT1 n=1, PLCG2 n=1, DKC1 n=1, POLA1 n=1), and 46 non-IBD controls. This effort resulted in the largest RNA-seq dataset of pediatric IBD intestinal epithelial organoids to date, encompassing both baseline conditions and post-immunological stimulation, serving as a valuable resource for future research. We observed that IEOs effectively initiate inflammation upon stimulation with bacterial lysate, regardless of disease status, origin, or mutation status. Inflammatory stimulation triggered single-gene upregulation of IBD-linked SERPINA1 and LIFR across the IBD population compared to controls, suggesting their role in intestinal epithelial innate immune responses. However, co-expression network analysis showed no consistent transcriptional signatures across the entire IBD group at the systems level. Instead, differences emerged between controls and specific genotypes ( TTC7A , STXBP2 , LRBA ), with STXBP2 and LRBA sharing an upregulated transcriptional response of IL-1 and SLC30-mediated zinc trafficking pathways. These findings underscore the potential of IEOs as a valuable model for studying IBD and offer key insights that could guide the development of targeted therapies for both monogenic and non-monogenic forms of IBD. Abstract Figure
Year:
2025
Pathogenic mutations in Tetratricopeptide repeat domain 7A ( TTC7A ) result in gastrointestinal and immunological disorders of which the pathobiology is not fully understood. Previous case reports indicate that TTC7A plays an important role in preserving intestinal epithelial integrity, but thus far only few variants have been investigated and it is unclear if different variants exert the same effects. Here, we aim to study the effects of different variants on the intestinal epithelium. We present three instances of pediatric inflammatory bowel disease (IBD), displaying varying clinical symptoms and severity levels, and associated with different heterozygous missense mutations in TTC7A . Intestinal organoids derived from patients show dissimilar epithelial phenotypes and exhibit differences in growth, morphology, apicobasal polarity, responses to specific drugs, TTC7A expression, and transcriptional profiles. The findings of our study suggest differences in pathobiology between individuals with different TTC7A mutations. This investigation enhances our comprehension of TTC7A-related conditions and can have implications for developing targeted therapies for TTC7A-associated disorders.
Year:
2025
Year:
2024
Monogenic causes of inflammatory bowel diseases (IBD) are increasingly being discovered. To date, much attention has been placed in those resulting from inborn errors of immunity. Therapeutic efforts have been largely focused on offering personalized immune modulation or curative bone marrow transplant for patients with IBD and underlying immune disorders. To date, less emphasis has been placed on monogenic causes of IBD that pertain to impairment of the intestinal epithelial barrier. Here, we provide a comprehensive review of monogenic causes of IBD that result in impaired intestinal epithelial barrier that are categorized into 6 important functions: (1) epithelial cell organization, (2) epithelial cell intrinsic functions, (3) epithelial cell apoptosis and necroptosis, (4) complement activation, (5) epithelial cell signaling, and (6) control of RNA degradation products. We illustrate how impairment of any of these categories can result in IBD. This work reviews the current understanding of the genes involved in maintaining the intestinal barrier, the inheritance patterns that result in dysfunction, features of IBD resulting from these disorders, and pertinent translational work in this field.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (12)
Holm Uhlig
Director Centre for Human Genetics
University of Oxford
Michal Mokry
Universitair Medisch Centrum Utrecht
Nadeem Ahmad Afzal
Associate Professor (Hon)
University of Southampton
Daniel Kotlarz
Lecturer, PhD program "Genomic and Molecular Medicine - Personalized Approaches to Childhood Health", "Modern Immunodiagnostics and FACS"
Dr von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universität München
Jeffrey Beekman
University Medical Center
Patrick van Rheenen
Pediatric Gastroenterologist, Head IBD Unit
University Medical Center Groningen
Christoph Klein
Professor of Pediatrics/Chair
LMU University Hospital
Johan H. van Es
Hubrecht Institute for Developmental Biology and Stem Cell Research
Ewart Kuijk
Assistant Professor
UMC Utrecht
Elizabeth Spencer
Associate Professor of Pediatric Gastroenterology & Nutrition
Mount Sinai Hospital
James Charlesworth
University of Oxford
Hans Clevers
Prof. dr
Utrecht University
Make your next move.
Prepare your application
Review drafts before you send them.